Highlights Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
1,006 ^USD	+1.27%		+4.07%	+14.53%

10:16pm	Regeneron Pharmaceuticals Insider Sold Shares Worth $1,115,422, According to a Recent SEC Filing	MT
02:30pm	Transcript : Regeneron Pharmaceuticals, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 08:30 AM

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier	Jun. 03	MT
Fibrogen, Inc. Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals, Inc. to Evaluate FibroGen's Immuno-Oncology Assets, Fg-3175 (Anti-Ccr8), in Upcoming Clinical Trials	Jun. 03	CI
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review	May. 31	RE
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months	May. 31	MT
Regeneron Pharmaceuticals, Inc and Sanofi Announce Dupixent® Recommends for EU Approval by the CHMP to Treat Patients with COPD	May. 31	CI
Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation	May. 31	CI
Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer	May. 23	MT
Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075	May. 23	CI
Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate	May. 20	MT
Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine	May. 20	CI
Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,000.25	May. 20	MT
Sector Update: Health Care Stocks Mixed Late Afternoon	May. 17	MT
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Younger CRSwNP Group	May. 13	DJ
Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Dupixent	May. 13	CI
Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks	May. 08	CI
Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple...	May. 02
Sector Update: Health Care Stocks Mixed Premarket Thursday	May. 02	MT
Regeneron: Adjusted EPS down 4% in Q1	May. 02	CF
Tranche Update on Regeneron Pharmaceuticals, Inc.'s Equity Buyback Plan announced on February 3, 2023.	May. 02	CI
Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales	May. 02	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Highlights

Filters